Phase I first-in-human study of RTA 1701.

Trial Profile

Phase I first-in-human study of RTA 1701.

Planning
Phase of Trial: Phase I

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs RTA 1701 (Primary)
  • Indications Autoimmune disorders; Inflammation
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 09 Apr 2018 New trial record
    • 03 Apr 2018 According to the Reata Pharmaceuticals media release, this trial expects to initiate in 2018 and initial results are expected in first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top